Policy Analysis: Life Sciences, Policy
Horizon 2020 Special Coverage
Horizon 2020 – New Commission, new Agenda
The 2015 Science|Business Horizon 2020 Conference
- 24 March 2015
The EU Energy Challenge: Can innovation fill the gap?
The EU’s transition to a sustainable energy system is a top policy challenge of the coming decade. Though much progress has been achieved, the pace of change is too slow.
Square - Brussels Meeting Centre - 13 November 2014
Heathcare biotech: New ideas for a healthier, wealthier Europe

European Parliament, Brussels - 09 October 2014
Helping Europe Innovate
The Annual Report 2013-2014 is a summary of the activites of the Science|Business Innovation Board over the past year. The Science|Business...
Published:
EU’S Innovative Medicines Initiative to collaborate with FDA’s Critical Path

US/European move to put more weight behind moves to improve drug development processes and increase’s R&D productivity in the pharmaceutical industry


Image: Bigstock

Europe’s Innovative Medicines Initiative (IMI) is joining forces with its US counterpart, the Critical Path Institute (C-Path) to further their shared mission of reshaping the drug development process to improve the productivity of pharmaceutical industry R&D.

Both organisations bring together scientists from the industry and academic institutions, with representatives from patient organisations, small companies and regulatory agencies, in precompetitive public-private partnerships.

By combining knowledge and expertise, these partnerships aim to tackle challenges that are too big and complex...



Related subjects: EU, USA

Advertisement